Down‐regulated LINC00115 inhibits prostate cancer cell proliferation and invasion via targeting miR‐212‐5p/FZD5/Wnt/β‐catenin axis. Issue 22 (26th October 2021)

• Record Type: Journal Article
• Authors: Peng, Naixiong; Zhang, Zejian; Wang, Yaomin; Yang, Minlong; Fan, Jiqing; Wang, Qinjun; Deng, Ling; Chen, Dong; Cai, Yuefeng; Li, Qihui; Wang, Xisheng; Li, Wei
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 22(2021)
• Page Start: 10627
• Page End: 10637
• Publication Date: 2021-10-26
• Subjects: invasion -- LINC00115 -- miR‐212‐5p -- proliferation -- prostate cancer; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.17000
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Prostate cancer is the second most frequent malignancy in men worldwide, and its incidence is increasing. Therefore, it is urgently required to clarify the underlying mechanisms of prostate cancer. Although the long non‐coding RNA LINC00115 was identified as an oncogene in several cancers, the expression and function of LINC00115 in prostate cancer have not been explored. Our results showed that LINC00115 was significantly up‐regulated in prostate cancer tissues, which was significantly associated with a poor prognosis for prostate cancer patients. Functional studies showed that knockdown LINC00115 inhibited cell proliferation and invasion. In addition, LINC00115 served as a competing endogenous RNA (ceRNA) through sponging miR‐212‐5p to release Frizzled Family Receptor 5 (FZD5) expression. The expression of miR‐212‐5p was noticeably low in tumour tissues, and FZD5 expression level was down‐regulated with the knockdown of LINC00115. Knockdown LINC00115 inhibited the Wnt/β‑catenin signalling pathway by inhibiting the expression of FZD5. Rescue experiments further showed that LINC00115 inhibits prostate cancer cell proliferation and invasion via targeting miR‐212‐5p/ FZD5/ Wnt/β‐catenin axis. The present study provided clues that LINC00115 may be a promising novel therapeutic target for prostate cancer patients.